×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRNS – marinus pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRNS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/6
03:35 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
1/29
02:01 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
1/21
02:02 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
1/13
02:11 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
1/6
06:06 pm
mrns
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
Low
Report
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
1/6
09:07 am
mrns
Kuehn Law Encourages MRNS, OMIC, LBRDA, and VCSA Investors to Contact Law Firm
Low
Report
Kuehn Law Encourages MRNS, OMIC, LBRDA, and VCSA Investors to Contact Law Firm
1/5
02:14 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/30
05:20 pm
mrns
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc. - MRNS
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc. - MRNS
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:00 pm
mrns
marinus pharmaceuticals, inc.
BEAT
Report
-12.4%
marinus pharmaceuticals, inc.
8/13/2024
07:00 am
mrns
marinus pharmaceuticals, inc.
MISS
Report
-4.1%
marinus pharmaceuticals, inc.
5/8/2024
07:00 am
mrns
marinus pharmaceuticals, inc.
IN-LINE
Report
-9.5%
marinus pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/11
08:46 pm
mrns
Form SCHEDULE 13G MARINUS PHARMACEUTICALS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Neutral
Report
Form SCHEDULE 13G MARINUS PHARMACEUTICALS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
2/11
08:21 pm
mrns
Form SCHEDULE 13G/A MARINUS PHARMACEUTICALS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Neutral
Report
Form SCHEDULE 13G/A MARINUS PHARMACEUTICALS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
2/11
11:08 am
mrns
Form SCHEDULE 13G/A MARINUS PHARMACEUTICALS, Filed by: FRANKLIN RESOURCES INC
Neutral
Report
Form SCHEDULE 13G/A MARINUS PHARMACEUTICALS, Filed by: FRANKLIN RESOURCES INC
2/11
09:20 am
mrns
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Ezickson Elan
Neutral
Report
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Ezickson Elan
2/11
09:19 am
mrns
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Fischer Seth H. Z.
Neutral
Report
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Fischer Seth H. Z.
2/11
09:18 am
mrns
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Hulihan Joseph
Neutral
Report
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Hulihan Joseph
2/11
09:18 am
mrns
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Johnson Marvin
Neutral
Report
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: Johnson Marvin
2/11
09:16 am
mrns
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: MANNING MARTHA E
Neutral
Report
Form 4 MARINUS PHARMACEUTICALS, For: Feb 07 Filed by: MANNING MARTHA E
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
Form 424B5 MARINUS PHARMACEUTICALS
52.1%
12/19 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 37.3%
3/19 Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications 37.3%
3/20 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 36.4%
7/25 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $3.00 price target on the stock. 24.4%
3/16 Form 10-K MARINUS PHARMACEUTICALS For: Dec 31 21.0%
2/14 Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 16.4%
2/24 Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences 16.3%
3/23 MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) 12.9%
9/26 Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial 12.7%
12/19 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 37.3%
3/19 Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications 37.3%
3/20 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 36.4%
7/25 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $3.00 price target on the stock. 24.4%
3/16 Form 10-K MARINUS PHARMACEUTICALS For: Dec 31 21.0%
2/14 Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 16.4%
2/24 Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences 16.3%
3/23 MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) 12.9%
9/26 Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial 12.7%
TOP News Decliners
7/23
Form 8-K MARINUS PHARMACEUTICALS For: Jul 23
-21.6%
3/16 Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results -20.7%
4/1 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -13.1%
9/26 Marinus up 58% premarket on positive ganaloxone data [Seeking Alpha] -11.5%
9/26 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -10.1%
10/17 Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting -7.6%
11/18 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -7.6%
10/29 Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer -7.5%
4/2 Form 8-K MARINUS PHARMACEUTICALS For: Mar 31 -7.5%
12/12 Form 424B5 MARINUS PHARMACEUTICALS -6.9%
3/16 Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results -20.7%
4/1 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -13.1%
9/26 Marinus up 58% premarket on positive ganaloxone data [Seeking Alpha] -11.5%
9/26 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -10.1%
10/17 Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting -7.6%
11/18 Marinus Pharmaceuticals Inc (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $5.00 price target on the stock. -7.6%
10/29 Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer -7.5%
4/2 Form 8-K MARINUS PHARMACEUTICALS For: Mar 31 -7.5%
12/12 Form 424B5 MARINUS PHARMACEUTICALS -6.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: